Pomalidomide

( DrugBank: Pomalidomide / KEGG DRUG: Pomalidomide )


5 diseases
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis9
51Scleroderma6
85Idiopathic interstitial pneumonia1
IDDisease name (Link within this page)Number of trials
227Osler disease2
331Idiopathic multicentric castleman disease1

28. Systemic amyloidosis


Clinical trials : 267Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 627Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

227. Osler disease


Clinical trials : 56Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

331. Idiopathic multicentric castleman disease


Clinical trials : 33Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries